|
Wednesday, July 14, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)
A Conversation with the Investigators: Acute Myeloid Leukemia and Myelodysplastic SyndromesA Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual MeetingJoin us on Wednesday, July 14th for this CME/MOC-accredited webinar Faculty
Courtney D DiNardo, MD, MSCE
Associate Professor, Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas Gail J Roboz, MD Director, Clinical and Translational Leukemia Programs Professor of Medicine Weill Cornell Medical College NewYork-Presbyterian Hospital New York, New York
Eytan M Stein, MD
Assistant Attending Physician Director, Program for Drug Development in Leukemia Leukemia Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York, New York Moderator Neil Love, MD Research To Practice Miami, Florida Management of Acute Myeloid Leukemia (AML) in Older Patients or Those Ineligible for Intensive Chemotherapy
Treatment Options for Patients with AML Harboring FLT3 Mutations
Management of AML with IDH Mutations
Tailoring Induction and Maintenance Therapy for Younger Patients with AML without Targetable Tumor Mutations
Treatment of AML Secondary to Myelodysplastic Syndromes (MDS) Transformation
Management Strategies for MDS
Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Disclosure Policy FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr DiNardo — Advisory Committee: Foghorn Therapeutics, Gilead Sciences Inc, Immune-Onc Therapeutics Inc, Novartis, Takeda Oncology; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Cleave Therapeutics, Daiichi Sankyo Inc, Immune-Onc Therapeutics Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Scientific Advisory Board with Stock Options: Notable Labs. Dr Roboz — Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals, Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Helsinn Healthcare SA, Janssen Biotech Inc, Jasper Therapeutics Inc, Jazz Pharmaceuticals Inc, MEI Pharma Inc (IDMC Chair), Mesoblast, Novartis, Otsuka America Pharmaceutical Inc, Pfizer Inc, Sandoz Inc, a Novartis Division, Takeda Oncology (IRC Chair); Contracted Research: Janssen Biotech Inc; Data and Safety Monitoring Board/Committee: MEI Pharma Inc, Takeda Oncology. Dr Stein — Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Ono Pharmaceutical Co Ltd, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, BioTheryX Inc, Bristol-Myers Squibb Company, Celgene Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Prelude Therapeutics, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |